Last week, Medtronic received FDA approval for its most deliverable drug eluting stent technology yet—the Resolute Integrity system, which seeks to provide enhanced procedural performance and comfort for physicians. The unique design of the stent showcases an innovative MicroTrac delivery system that improves tracking of the catheter and contains biocompitable BioLinx polymer, which extends drug elution.
FDA-approved resolute integrity DES system promises superior deliverability
The rubidium generator recall is now over, allowing cardiac imaging administrators to breathe a sigh of relief. The recall had halted cardiac PET services for the past several months after the FDA initiated an investigation in mid-2011 regarding excessive radiation exposure.
Recall aside, the past several years have been difficult for planners of cardiac imaging services, and careful strategic planning is necessary before making an investment in cardiac PET technology.
Cardiac PET resurgence? Strategic planning required
As hospitals have seen their birth rates continue to decline across the past five years, administrators are searching for new ways to attract patients to deliver at their organizations. Historically, hospitals focused on promoting high risk obstetrics services and NICUs to assure patients that—if needed—they would receive the most advanced care possible.
Re-emphasizing the value of communication in obstetrical care